The  ||| S:0 E:4 ||| DT
impact  ||| S:4 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
host  ||| S:18 E:23 ||| NN
on  ||| S:23 E:26 ||| IN
fungal  ||| S:26 E:33 ||| JJ
infections  ||| S:33 E:44 ||| JJ
Outcomes  ||| S:44 E:53 ||| NNS
of  ||| S:53 E:56 ||| IN
fungal  ||| S:56 E:63 ||| JJ
infections  ||| S:63 E:74 ||| NNS
in  ||| S:74 E:77 ||| IN
immunocompromised  ||| S:77 E:95 ||| JJ
individuals  ||| S:95 E:107 ||| NNS
depend  ||| S:107 E:114 ||| VBP
on  ||| S:114 E:117 ||| IN
a  ||| S:117 E:119 ||| DT
complex  ||| S:119 E:127 ||| JJ
interplay  ||| S:127 E:137 ||| NN
between  ||| S:137 E:145 ||| IN
host  ||| S:145 E:150 ||| NN
and  ||| S:150 E:154 ||| CC
pathogen  ||| S:154 E:163 ||| JJ
factors ||| S:163 E:170 ||| NNS
,  ||| S:170 E:172 ||| ,
as  ||| S:172 E:175 ||| RB
well  ||| S:175 E:180 ||| RB
as  ||| S:180 E:183 ||| IN
treatment  ||| S:183 E:193 ||| NN
modalities ||| S:193 E:203 ||| NN
.  ||| S:203 E:205 ||| .
Problems  ||| S:205 E:214 ||| NNS
occur  ||| S:214 E:220 ||| VBP
when  ||| S:220 E:225 ||| WRB
host  ||| S:225 E:230 ||| NN
responses  ||| S:230 E:240 ||| NNS
to  ||| S:240 E:243 ||| TO
an  ||| S:243 E:246 ||| DT
infection  ||| S:246 E:256 ||| NN
are  ||| S:256 E:260 ||| VBP
either  ||| S:260 E:267 ||| RB
too  ||| S:267 E:271 ||| RB
weak  ||| S:271 E:276 ||| JJ
to  ||| S:276 E:279 ||| TO
effectively  ||| S:279 E:291 ||| RB
help  ||| S:291 E:296 ||| VB
eradicate  ||| S:296 E:306 ||| VB
the  ||| S:306 E:310 ||| DT
pathogen ||| S:310 E:318 ||| NN
,  ||| S:318 E:320 ||| ,
or  ||| S:320 E:323 ||| CC
when  ||| S:323 E:328 ||| WRB
they  ||| S:328 E:333 ||| PRP
become  ||| S:333 E:340 ||| VBP
too  ||| S:340 E:344 ||| RB
strong  ||| S:344 E:351 ||| JJ
and  ||| S:351 E:355 ||| CC
are  ||| S:355 E:359 ||| VBP
associated  ||| S:359 E:370 ||| VBN
with  ||| S:370 E:375 ||| IN
host  ||| S:375 E:380 ||| NN
damage  ||| S:380 E:387 ||| NN
rather  ||| S:387 E:394 ||| RB
than  ||| S:394 E:399 ||| IN
protection ||| S:399 E:409 ||| NN
.  ||| S:409 E:411 ||| .
Immune  ||| S:411 E:418 ||| JJ
reconstitution  ||| S:418 E:433 ||| JJ
syndrome  ||| S:433 E:442 ||| NN
( ||| S:442 E:443 ||| -LRB-
IRS ||| S:443 E:446 ||| NNP
)  ||| S:446 E:448 ||| -RRB-
can  ||| S:448 E:452 ||| MD
be  ||| S:452 E:455 ||| VB
generally  ||| S:455 E:465 ||| RB
defined  ||| S:465 E:473 ||| VBN
as  ||| S:473 E:476 ||| IN
a  ||| S:476 E:478 ||| DT
restoration  ||| S:478 E:490 ||| NN
of  ||| S:490 E:493 ||| IN
host  ||| S:493 E:498 ||| NN
immunity  ||| S:498 E:507 ||| NN
in  ||| S:507 E:510 ||| IN
a  ||| S:510 E:512 ||| DT
previously  ||| S:512 E:523 ||| RB
immunosuppressed  ||| S:523 E:540 ||| JJ
patient  ||| S:540 E:548 ||| NN
that  ||| S:548 E:553 ||| WDT
becomes  ||| S:553 E:561 ||| VBZ
dysregulated  ||| S:561 E:574 ||| VBN
and  ||| S:574 E:578 ||| CC
overly  ||| S:578 E:585 ||| RB
robust ||| S:585 E:591 ||| JJ
,  ||| S:591 E:593 ||| ,
resulting  ||| S:593 E:603 ||| VBG
in  ||| S:603 E:606 ||| IN
host  ||| S:606 E:611 ||| NN
damage  ||| S:611 E:618 ||| NN
and  ||| S:618 E:622 ||| CC
sometimes  ||| S:622 E:632 ||| RB
death ||| S:632 E:637 ||| NN
.  ||| S:637 E:639 ||| .
IRS  ||| S:639 E:643 ||| NNP
associated  ||| S:643 E:654 ||| VBN
with  ||| S:654 E:659 ||| IN
opportunistic  ||| S:659 E:673 ||| JJ
mycoses  ||| S:673 E:681 ||| NN
presents  ||| S:681 E:690 ||| VBZ
as  ||| S:690 E:693 ||| RB
new  ||| S:693 E:697 ||| JJ
or  ||| S:697 E:700 ||| CC
worsening  ||| S:700 E:710 ||| VBG
clinical  ||| S:710 E:719 ||| JJ
symptoms  ||| S:719 E:728 ||| NNS
or  ||| S:728 E:731 ||| CC
radiographic  ||| S:731 E:744 ||| JJ
signs  ||| S:744 E:750 ||| NNS
consistent  ||| S:750 E:761 ||| JJ
with  ||| S:761 E:766 ||| IN
an  ||| S:766 E:769 ||| DT
inflammatory  ||| S:769 E:782 ||| JJ
process  ||| S:782 E:790 ||| NN
that  ||| S:790 E:795 ||| WDT
occur  ||| S:795 E:801 ||| VBP
during  ||| S:801 E:808 ||| IN
receipt  ||| S:808 E:816 ||| NN
of  ||| S:816 E:819 ||| IN
an  ||| S:819 E:822 ||| DT
appropriate  ||| S:822 E:834 ||| JJ
antifungal ||| S:834 E:844 ||| NN
,  ||| S:844 E:846 ||| ,
and  ||| S:846 E:850 ||| CC
that  ||| S:850 E:855 ||| IN
cannot  ||| S:855 E:862 ||| RB
be  ||| S:862 E:865 ||| VB
explained  ||| S:865 E:875 ||| VBN
by  ||| S:875 E:878 ||| IN
a  ||| S:878 E:880 ||| DT
newly  ||| S:880 E:886 ||| RB
acquired  ||| S:886 E:895 ||| VBN
infection ||| S:895 E:904 ||| NN
.  ||| S:904 E:906 ||| .
Because  ||| S:906 E:914 ||| IN
there  ||| S:914 E:920 ||| EX
are  ||| S:920 E:924 ||| VBP
currently  ||| S:924 E:934 ||| RB
no  ||| S:934 E:937 ||| DT
established  ||| S:937 E:949 ||| JJ
tests  ||| S:949 E:955 ||| NNS
or  ||| S:955 E:958 ||| CC
biomarkers  ||| S:958 E:969 ||| NN
for  ||| S:969 E:973 ||| IN
IRS ||| S:973 E:976 ||| NNP
,  ||| S:976 E:978 ||| ,
it  ||| S:978 E:981 ||| PRP
can  ||| S:981 E:985 ||| MD
be  ||| S:985 E:988 ||| VB
difficult  ||| S:988 E:998 ||| JJ
to  ||| S:998 E:1001 ||| TO
distinguish  ||| S:1001 E:1013 ||| VB
from  ||| S:1013 E:1018 ||| IN
progression  ||| S:1018 E:1030 ||| NN
of  ||| S:1030 E:1033 ||| IN
the  ||| S:1033 E:1037 ||| DT
original  ||| S:1037 E:1046 ||| JJ
infection ||| S:1046 E:1055 ||| NN
,  ||| S:1055 E:1057 ||| ,
although  ||| S:1057 E:1066 ||| IN
culture  ||| S:1066 E:1074 ||| NN
and  ||| S:1074 E:1078 ||| CC
biomarkers  ||| S:1078 E:1089 ||| NN
for  ||| S:1089 E:1093 ||| IN
the  ||| S:1093 E:1097 ||| DT
fungal  ||| S:1097 E:1104 ||| JJ
pathogen  ||| S:1104 E:1113 ||| NN
or  ||| S:1113 E:1116 ||| CC
infection  ||| S:1116 E:1126 ||| NNS
are  ||| S:1126 E:1130 ||| VBP
typically  ||| S:1130 E:1140 ||| RB
negative  ||| S:1140 E:1149 ||| JJ
during  ||| S:1149 E:1156 ||| IN
diagnostic  ||| S:1156 E:1167 ||| JJ
workup ||| S:1167 E:1173 ||| NN
.  ||| S:1173 E:1175 ||| .
IRS  ||| S:1175 E:1179 ||| NNP
was  ||| S:1179 E:1183 ||| VBD
originally  ||| S:1183 E:1194 ||| RB
characterized  ||| S:1194 E:1208 ||| VBN
in  ||| S:1208 E:1211 ||| IN
human  ||| S:1211 E:1217 ||| JJ
immunodeficiency  ||| S:1217 E:1234 ||| JJ
virus-infected  ||| S:1234 E:1249 ||| JJ
patients  ||| S:1249 E:1258 ||| NNS
receiving  ||| S:1258 E:1268 ||| VBG
antiretroviral  ||| S:1268 E:1283 ||| JJ
therapy ||| S:1283 E:1290 ||| NN
,  ||| S:1290 E:1292 ||| ,
but  ||| S:1292 E:1296 ||| CC
has  ||| S:1296 E:1300 ||| VBZ
subsequently  ||| S:1300 E:1313 ||| RB
been  ||| S:1313 E:1318 ||| VBN
described  ||| S:1318 E:1328 ||| VBN
in  ||| S:1328 E:1331 ||| IN
solid-organ  ||| S:1331 E:1343 ||| JJ
transplant  ||| S:1343 E:1354 ||| NN
recipients ||| S:1354 E:1364 ||| NNS
,  ||| S:1364 E:1366 ||| ,
neutropenic  ||| S:1366 E:1378 ||| JJ
patients ||| S:1378 E:1386 ||| NNS
,  ||| S:1386 E:1388 ||| ,
women  ||| S:1388 E:1394 ||| NNS
in  ||| S:1394 E:1397 ||| IN
the  ||| S:1397 E:1401 ||| DT
postpartum  ||| S:1401 E:1412 ||| JJ
period ||| S:1412 E:1418 ||| NN
,  ||| S:1418 E:1420 ||| ,
and  ||| S:1420 E:1424 ||| CC
recipients  ||| S:1424 E:1435 ||| NNS
of  ||| S:1435 E:1438 ||| IN
tumor  ||| S:1438 E:1444 ||| NN
necrosis  ||| S:1444 E:1453 ||| VBZ
factor-Î±  ||| S:1453 E:1462 ||| JJ
inhibitor  ||| S:1462 E:1472 ||| JJ
therapy ||| S:1472 E:1479 ||| NN
.  ||| S:1479 E:1481 ||| .
In  ||| S:1481 E:1484 ||| IN
each  ||| S:1484 E:1489 ||| DT
of  ||| S:1489 E:1492 ||| IN
these  ||| S:1492 E:1498 ||| DT
cases ||| S:1498 E:1503 ||| NNS
,  ||| S:1503 E:1505 ||| ,
recovery  ||| S:1505 E:1514 ||| NN
of  ||| S:1514 E:1517 ||| IN
the  ||| S:1517 E:1521 ||| DT
host ||| S:1521 E:1525 ||| NN
's  ||| S:1525 E:1528 ||| POS
immunity  ||| S:1528 E:1537 ||| NN
during  ||| S:1537 E:1544 ||| IN
treatment  ||| S:1544 E:1554 ||| NN
of  ||| S:1554 E:1557 ||| IN
an  ||| S:1557 E:1560 ||| DT
initial  ||| S:1560 E:1568 ||| JJ
infection  ||| S:1568 E:1578 ||| NN
results  ||| S:1578 E:1586 ||| NNS
in  ||| S:1586 E:1589 ||| IN
a  ||| S:1589 E:1591 ||| DT
powerful  ||| S:1591 E:1600 ||| JJ
proinflammatory  ||| S:1600 E:1616 ||| JJ
environment  ||| S:1616 E:1628 ||| NN
that  ||| S:1628 E:1633 ||| IN
overshoots  ||| S:1633 E:1644 ||| NN
and  ||| S:1644 E:1648 ||| CC
leads  ||| S:1648 E:1654 ||| VBZ
to  ||| S:1654 E:1657 ||| TO
host  ||| S:1657 E:1662 ||| VB
damage ||| S:1662 E:1668 ||| NN
.  ||| S:1668 E:1670 ||| .
Optimal  ||| S:1670 E:1678 ||| JJ
management  ||| S:1678 E:1689 ||| NN
of  ||| S:1689 E:1692 ||| IN
IRS  ||| S:1692 E:1696 ||| NNP
has  ||| S:1696 E:1700 ||| VBZ
not  ||| S:1700 E:1704 ||| RB
been  ||| S:1704 E:1709 ||| VBN
established  ||| S:1709 E:1721 ||| VBN
at  ||| S:1721 E:1724 ||| IN
present ||| S:1724 E:1731 ||| JJ
,  ||| S:1731 E:1733 ||| ,
but  ||| S:1733 E:1737 ||| CC
often  ||| S:1737 E:1743 ||| RB
involves  ||| S:1743 E:1752 ||| VBZ
treatment  ||| S:1752 E:1762 ||| NN
with  ||| S:1762 E:1767 ||| IN
a  ||| S:1767 E:1769 ||| DT
corticosteroid  ||| S:1769 E:1784 ||| NN
or  ||| S:1784 E:1787 ||| CC
other  ||| S:1787 E:1793 ||| JJ
anti-inflammatory  ||| S:1793 E:1811 ||| JJ
compounds ||| S:1811 E:1820 ||| NN
.  ||| S:1820 E:1822 ||| .
This  ||| S:1822 E:1827 ||| DT
article  ||| S:1827 E:1835 ||| NN
uses  ||| S:1835 E:1840 ||| VBZ
a  ||| S:1840 E:1842 ||| DT
number  ||| S:1842 E:1849 ||| NN
of  ||| S:1849 E:1852 ||| IN
patient  ||| S:1852 E:1860 ||| JJ
cases  ||| S:1860 E:1866 ||| NNS
to  ||| S:1866 E:1869 ||| TO
explore  ||| S:1869 E:1877 ||| VB
the  ||| S:1877 E:1881 ||| DT
intricacies  ||| S:1881 E:1893 ||| NN
of  ||| S:1893 E:1896 ||| IN
diagnosing  ||| S:1896 E:1907 ||| NN
and  ||| S:1907 E:1911 ||| CC
managing  ||| S:1911 E:1920 ||| VBG
a  ||| S:1920 E:1922 ||| DT
patient  ||| S:1922 E:1930 ||| NN
with  ||| S:1930 E:1935 ||| IN
IRS ||| S:1935 E:1938 ||| NNP
,  ||| S:1938 E:1940 ||| ,
as  ||| S:1940 E:1943 ||| RB
well  ||| S:1943 E:1948 ||| RB
as  ||| S:1948 E:1951 ||| IN
the  ||| S:1951 E:1955 ||| DT
other  ||| S:1955 E:1961 ||| JJ
extreme ||| S:1961 E:1968 ||| NN
,  ||| S:1968 E:1970 ||| ,
namely  ||| S:1970 E:1977 ||| JJ
patients  ||| S:1977 E:1986 ||| NNS
who  ||| S:1986 E:1990 ||| WP
are  ||| S:1990 E:1994 ||| VBP
so  ||| S:1994 E:1997 ||| RB
immunocompromised  ||| S:1997 E:2015 ||| VBN
without  ||| S:2015 E:2023 ||| IN
immune  ||| S:2023 E:2030 ||| JJ
recovery  ||| S:2030 E:2039 ||| NN
that  ||| S:2039 E:2044 ||| IN
they  ||| S:2044 E:2049 ||| PRP
essentially  ||| S:2049 E:2061 ||| RB
become  ||| S:2061 E:2068 ||| VB
breeding  ||| S:2068 E:2077 ||| VBG
grounds  ||| S:2077 E:2085 ||| NNS
for  ||| S:2085 E:2089 ||| IN
a  ||| S:2089 E:2091 ||| DT
wide  ||| S:2091 E:2096 ||| JJ
range  ||| S:2096 E:2102 ||| NN
of  ||| S:2102 E:2105 ||| IN
opportunistic  ||| S:2105 E:2119 ||| JJ
pathogens ||| S:2119 E:2128 ||| NN
,  ||| S:2128 E:2130 ||| ,
often  ||| S:2130 E:2136 ||| RB
simultaneously ||| S:2136 E:2150 ||| RB
.  ||| S:2150 E:2152 ||| .
